EUVIMEDEUVIMED entdecken
Crossref

Identification of CDKN1A as a potential key risk factor in MASLD progression

Lijuan Deng iD, Jianxin Deng iD, Liping Luo iD, Hongjia Yang iD, Mengxue Sun iD, Yucheng Gao iD, Qing Liu iD, Ebenezeri Erasto Ngowi iD, Yinghua Zhou iD, Rongrong Zhang iD, Xiaojun Liu iD, Aijun Qiao iD

The FASEB Journal · 15.04.2025 · 39 (7)

DOI: 10.1096/fj.202402942r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 11.04.2025. Verfasst von Lijuan Deng und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Cyclin-Dependent Kinase Inhibitor p21. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), High-level New R&D Institute of Department of Science and Technology of Guangdong Province, High-level Innovative Research Institute of Department of Science and Technology of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐associated steatotic liver disease (MASLD), previously referred to as non‐alcoholic fatty liver disease (NAFLD), is recognized as a highly heterogeneous condition. The elusive mechanisms driving its progression contribute to the lack of reliable diagnostic markers and effective treatments. In this study, we first identified 52 differentially expressed genes (DEGs) in MASLD stage by analyzing two public datasets, GSE126848 and GSE135251, using the DESeq2 and edgeR packages. Subsequently, these DEGs were subjected to protein–protein interaction (PPI) network analysis, revealing the top 10 hub genes. By intersecting the top 10 hub genes with another public dataset GSE260222, we observed that CDKN1A was the sole gene consistently upregulated in the livers of MASLD patients across all analyses. The elevated protein expression of CDKN1A was further validated in the livers of MASLD patients compared to control subjects. Consistently, compared to their respective control groups, both CDKN1A mRNA and protein levels were dramatically increased in the livers of MASLD animal models, including high‐fat diet (HFD) induced obese mice, leptin‐deficient obese ( ob/ob ) mice and leptin receptor‐deficient ( db/db ) mice, and in mouse primary hepatocytes treated with free fatty acids (FFA), respectively. Interestingly, we found that CDKN1A transcript levels were progressively and significantly increased with the severity of MASLD in four out of five datasets and positively correlated with both the NAFLD activity score (NAS) and fibrosis stage, two important clinicopathological features of MASLD. Collectively, our results illustrated that CDKN1A may serve as a promising biomarker and therapeutic target for MASLD; however, its role in the disease's pathology warrants further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseCyclin-Dependent Kinase Inhibitor p21AnimalsHumansMiceDisease ProgressionMaleRisk FactorsMice, Inbred C57BLDiet, High-FatMice, ObeseLiverProtein Interaction MapsObesityFemale

Stichwörter der Autor:innen

CDKN1AMASLDRNA‐seqbiomarkersliver

Substanzen

Cyclin-Dependent Kinase Inhibitor p21CDKN1A protein, human

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
  • Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, Guangdong, China.
  • Department of Endocrinology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen Clinical Research Center for Metabolic Diseases, Shenzhen Center for Diabetes Control and Pr…
  • School of Pharmacy, Zunyi Medical University, Zhuhai, Guangdong, China.
  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • University of Chinese Academy of Sciences, Beijing, China.

ORCID-Profile: Lijuan Deng, Jianxin Deng, Liping Luo, Hongjia Yang, Mengxue Sun, Yucheng Gao, Qing Liu, Ebenezeri Erasto Ngowi, Yinghua Zhou, Rongrong Zhang, Xiaojun Liu, Aijun Qiao

Förderung

  • MOST | National Natural Science Foundation of China (NSFC)
  • High-level New R&D Institute of Department of Science and Technology of Guangdong Province
  • High-level Innovative Research Institute of Department of Science and Technology of Guangdong Province
  • Zhongshan Science and Technology Bureau
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
  • Beijing Natural Science Foundation
  • Shenzhen Science and Technology Program
  • National Natural Science Foundation of China

Zitieren

APA

Deng, L., Deng, J., Luo, L., Yang, H., Sun, M., Gao, Y., Liu, Q., Ngowi, E. E., Zhou, Y., Zhang, R., Liu, X., & Qiao, A. (2025). Identification of CDKN1A as a potential key risk factor in MASLD progression. The FASEB Journal, 39(7). https://doi.org/10.1096/fj.202402942r

Vancouver

Deng L, Deng J, Luo L, Yang H, Sun M, Gao Y, et al. Identification of CDKN1A as a potential key risk factor in MASLD progression. The FASEB Journal. 2025;39(7). doi:10.1096/fj.202402942r

BibTeX
@article{Deng2025,
  author = {Deng, Lijuan and Deng, Jianxin and Luo, Liping and Yang, Hongjia and Sun, Mengxue and Gao, Yucheng and Liu, Qing and Ngowi, Ebenezeri Erasto and Zhou, Yinghua and Zhang, Rongrong and Liu, Xiaojun and Qiao, Aijun},
  title = {Identification of CDKN1A as a potential key risk factor in MASLD progression},
  journal = {The FASEB Journal},
  year = {2025},
  volume = {39},
  number = {7},
  doi = {10.1096/fj.202402942r}
}
Kostenlos starten →